Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Johnson

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinasesGary T Wang, Robert A Mantei, Robert D Hubbard, et al.
Molecular Cancer Research : MCR|July 29, 2015
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP InhibitorsTodd A Hopkins, Yan Shi, Luis E Rodriguez, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Molecular Cancer Research : MCR|October 15, 2009
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathwaysXuesong Liu, Edward K Han, Mark Anderson, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Bioorganic & Medicinal Chemistry|July 7, 2012
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancerGui-Dong Zhu, Jianchun Gong, Viraj B Gandhi, et al.
BMC Cancer|September 8, 2009
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605William N Pappano, Paul M Jung, Jonathan A Meulbroek, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinasesRobert D Hubbard, Nwe Y Bamaung, Steve D Fidanze, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2008
Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitorsVijaya Gracias, Zhiqin Ji, Irini Akritopoulou-Zanze, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.
Bioorganic & Medicinal Chemistry Letters|September 7, 2010
Substituted 4-amino-1H-pyrazolo[3,4-d]pyrimidines as multi-targeted inhibitors of insulin-like growth factor-1 receptor (IGF1R) and members of ErbB-family receptor kinasesGary T Wang, Robert A Mantei, Robert D Hubbard, et al.
Molecular Cancer Research : MCR|July 29, 2015
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP InhibitorsTodd A Hopkins, Yan Shi, Luis E Rodriguez, et al.
Bioorganic & Medicinal Chemistry Letters|July 1, 2008
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituentGui-Dong Zhu, Viraj B Gandhi, Jianchun Gong, et al.
Molecular Cancer Research : MCR|October 15, 2009
Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathwaysXuesong Liu, Edward K Han, Mark Anderson, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinaseYunsong Tong, Maricel Torrent, Alan S Florjancic, et al.
Bioorganic & Medicinal Chemistry|July 7, 2012
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancerGui-Dong Zhu, Jianchun Gong, Viraj B Gandhi, et al.
BMC Cancer|September 8, 2009
Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605William N Pappano, Paul M Jung, Jonathan A Meulbroek, et al.
Bioorganic & Medicinal Chemistry Letters|February 17, 2009
Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinasesRobert D Hubbard, Nwe Y Bamaung, Steve D Fidanze, et al.
Bioorganic & Medicinal Chemistry Letters|March 26, 2008
Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitorsVijaya Gracias, Zhiqin Ji, Irini Akritopoulou-Zanze, et al.
Pageof 13